CD86 and neoplasm: CTLA4-CD80/CD86 signal initiates T cells anergy or exhaustion, which reduces the activities of T cells, whereas blockade of the interaction between CTLA4 and its ligands reverses effector T cells exhaustion, thereby reinforcing anti-tumor activities of T cells (6).